StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
PTRK.ST$7.68-2.57%
Fair $7.68+0.0%

PTRK.ST

Physitrack PLC

Healthcare / Health Information ServicesStockholm

$7.68

-0.20 (-2.57%)

Fairly Valued+0.0%Fair Value $7.68Fund rank 26/100 · Data gapFallback financials|
SA 14/F
F-Score: 3/9
Low Profitability

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 18%

FCF escenarios

weak_data · normalized FCF $-773782.00 · quality 49.3/100

Data gap 26/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 17/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

14/100

F

Piotroski

3/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

12/100

SEC 0%

Latest source: unknownPeriods: 3Warnings: 1unknown: 3
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified. ROE is -33.7%, below the 5% threshold
Thesis & Journal · PTRK.STLocal privado en este navegador · Physitrack PLC
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$125M

P/E

N/A

•

EV/EBITDA

N/A

•

ROE

-33.7%

↓

Gross Margin

100.0%

↑

Debt/Equity

0.25

↑
52-Week Range$8
$8$22

TradingView lightweight chart

PTRK.ST price, volumen y niveles de valoración

Último $7.580Periodo -83.7%
Fair value: $7.680

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2024 · 2 años de histórico normalizado

Revenue CAGR

+13.7%

FCF CAGR

—

FCF margin

-2.2%

FCF / Net income

0.06x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $16.2M · net income $-6.5M · FCF $-363543.0

2022-FY → 2024-FY

Gross margin

100.0%+0.0% pts

Operating margin

-12.4%-9.3% pts

Net margin

-39.9%-40.6% pts

FCF margin

-2.2%+22.1% pts
MetricTTM
2024
2023
2022
Income Statement
Revenue$16.2M$16.2M$14.7M$12.5M
Net Income$-6.5M$-6.5M$2.8M$92319.00
EBITDA$-2.1M$-2.1M$6.7M$2.6M
EPS-0.40-0.400.170.01
Gross Margin100.0%100.0%100.0%100.0%
Operating Margin-12.4%-12.4%-6.4%-3.1%
Net Margin-39.9%-39.9%19.1%0.7%
Balance Sheet
Debt/Equity0.250.250.140.04
Current Ratio0.440.44——
Cash Flow
Free Cash Flow$-363543.00$-363543.00$-773782.00$-3.0M
Returns
ROE-33.7%-33.7%11.2%0.4%
Valuation
P/E——95.882340.00
EV/EBITDA——40.28148.05
P/B6.526.5210.5517.06
Growth & Yield
Revenue Growth9.7%9.7%17.9%—
EPS Growth-335.3%-335.3%1600.0%—

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -37.4%

Total return

-37.4%

Start / end P/E

n/dx → n/dx

EPS bridge

0.17 → -0.40

Residual

-37.4%

EPS growthn/d
Multiple reratingn/d
Dividend+0.0%
Residual / FX / buybacks / cross-term-37.4%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.